We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Centers for Disease Control and Prevention (CDC) has decided that the likelihood of an avian influenza pandemic is less than previously thought.
India-based Panacea Biotec has received prequalification accreditation from the World Health Organization (WHO) to supply its recombinant hepatitis B vaccine to U.N. agencies.
Teva Pharmaceuticals' chances of continuing to neutralize the risk involved in legal battles with the innovative drugmakers through out-of-court settlements are growing slimmmer.
YM BioSciences Inc., a company engaged in the acquisition, development and commercialization of oncology and acute care products, announced that its majority owned subsidiary, CIMYM BioSciences Inc., has licensed development and marketing rights in Japan for its anti-EGFR humanized antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED, one of Japan's largest pharmaceutical companies).
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., has received official notification from the Committee on Orphan Medical Products (COMP) of the European Medicines Agency that a positive opinion was made regarding the application for orphan medicinal product designation for BiovaxID the company's autologous immunotherapy for the treatment of follicular lymphoma in the European Union (EU).
Novo Nordisk announced that the European Commission has approved the rapid-acting insulin NovoRapid (insulin aspart) for use by pregnant women with diabetes.
Canadian pharmaceutical company Biovail Corp. said Monday that staff of the Ontario Securities Commission have filed administrative allegations against the company's chairman and former CEO, Eugene Melnyk, and a former Biovail director, among others.